Authors: SPIELBERG S MCCREA J CRIBB A RUSHMORE T WALDMAN S BJORNSSON T LO MW GOLDBERG M

Citation: S. Spielberg et al., A MUTATION IN CYP2C9 IS RESPONSIBLE FOR DECREASED METABOLISM OF LOSARTAN, Clinical pharmacology and therapeutics, 59(2), 1996, p.

Authors: MCCREA J LO MW KONG T CRIBB A GOLDBERG M BJORNSSON T

Citation: J. Mccrea et al., RARE DEFICIENCY OF THE CONVERSION OF LOSARTAN TO ITS ACTIVE METABOLITE, E3174, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 154-154

Authors: THULIN T ALMKVIST H BERGLUND L BJORNSSON T FAGHER B HENNINGSEN N HONKAVAARA M NAUKKARINEN V NORDENSTROM P SILLANPAA J WEST K

Citation: T. Thulin et al., EFFICACY AND TOLERABILITY OF FELODIPINE ER AND DILTIAZEM SR AS MONOTHERAPY IN PRIMARY HYPERTENSION - A DOUBLE-BLIND RANDOMIZED STUDY, Cardiovascular drugs and therapy, 8(6), 1994, pp. 845-849

Authors: SQUIRES KE SAAG MS TEPPLER H POMERANTZ R WALDMAN S BJORNSSON T WOOLF E YEH K EMINI E DEUTSCH P

Citation: Ke. Squires et al., PHASE-I STUDIES OF L-735,524, AN HIV PROTEASE INHIBITOR - PHARMACOKINETICS, TOLERABILITY AND SHORT-TERM ANTIVIRAL ACTIVITY, Clinical research, 42(2), 1994, pp. 10000280-10000280

Authors: SCHWARTZ J YEH K BERGER M BJORNSSON T TOMASKO L

Citation: J. Schwartz et al., NOVEL ORAL MEDICATION DELIVERY SYSTEM FOR FAMOTIDINE, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 185-185